NASDAQ · Financial Statements

Kymera Therapeutics, Inc. (KYMR) Financial Statements

$110.76 NASDAQ: KYMR Market Cap $9.11B

Kymera Therapeutics, Inc. most recently reported annual revenue of $39.0M, a net loss of $311.0M. Revenue grew at an average annual rate of 2.8% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Kymera Therapeutics, Inc.: net profit was positive in 0 of 8 reported years; operating margin moved from -1438.5% to -891.3%, a shift of +547.1 percentage points; the most recent year shows a net loss of $311.0M.

Income Statement — 8 Years (USD millions)

Metric20182019202020212022202320242025
Revenue$0$3.0M$34.0M$73.0M$47.0M$79.0M$47.0M$39.0M
Operating Expenses$21.0M$45.0M$80.0M$173.0M$208.0M$244.0M$309.0M$389.0M
Operating Profit$-21.0M$-42.0M$-46.0M$-101.0M$-161.0M$-166.0M$-262.0M$-349.0M
Operating Margin0.0%-1438.5%-136.1%-138.0%-344.4%-210.6%-555.8%-891.3%
Other Income$0$1.0M$1.0M$0$6.0M$19.0M$38.0M$38.0M
Interest$0$0$0$0$0$0$0$0
Depreciation$0$1.0M$2.0M$2.0M$3.0M$4.0M$7.0M$8.0M
Profit Before Tax$-21.0M$-41.0M$-46.0M$-100.0M$-155.0M$-147.0M$-224.0M$-312.0M
Tax$-200,000$0$0$0$0$0$0$0
Net Profit$-21.0M$-41.0M$-46.0M$-100.0M$-155.0M$-147.0M$-224.0M$-311.0M
EPS$-0.48$-0.93$-0.99$-2.09$-2.87$-2.52$-2.98$-3.69
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$5.0M$48.0M$10.0M$26.0M$4.0M$7.0M$22.0M$11.0M$3.0M$3.0M$34.0M$65.0M
Operating Expenses$62.0M$67.0M$68.0M$77.0M$76.0M$88.0M$97.0M$96.0M$95.0M$101.0M$119.0M$141.0M
Operating Profit$-58.0M$-19.0M$-58.0M$-51.0M$-72.0M$-81.0M$-74.0M$-85.0M$-93.0M$-98.0M$-84.0M$-76.0M
Operating Margin-1216.3%-40.3%-562.2%-198.5%-1927.9%-1092.2%-336.8%-736.8%-3347.4%-3422.9%-244.9%-116.3%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-53.0M$-14.0M$-49.0M$-42.0M$-62.0M$-71.0M$-66.0M$-77.0M$-82.0M$-87.0M$-69.0M$-61.0M
Tax$0$0$0$0$0$0$0$0$0$0$0$0
Net Profit$-53.0M$-14.0M$-49.0M$-42.0M$-62.0M$-71.0M$-66.0M$-77.0M$-82.0M$-87.0M$-69.0M$-61.0M
EPS$-0.90$-0.25$-0.69$-0.58$-0.82$-0.88$-0.82$-0.95$-0.94$-0.98$-0.71$-0.62

Over the 8 years reported for Kymera Therapeutics, Inc., borrowings increased from $1.0M in 2018 to $82.0M in 2025, cash stood at $357.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 10.49 times.

Balance Sheet — 8 Years (USD millions)

Metric20182019202020212022202320242025
Total Assets$44.0M$117.0M$487.0M$606.0M$603.0M$576.0M$978.0M$1.7B
Current Assets$42.0M$93.0M$302.0M$451.0M$419.0M$405.0M$510.0M$871.0M
Cash$41.0M$76.0M$31.0M$48.0M$68.0M$110.0M$120.0M$357.0M
Inventory$0$0$0$0$0$0$0$0
Receivables$0$0$1.0M$0$3.0M$19.0M$1.0M$0
Fixed Assets$2.0M$22.0M$21.0M$21.0M$22.0M$101.0M$98.0M$86.0M
Capital Work in Progress$0$0$0$0$0$0$0$0
Investments$0$16.0M$428.0M$520.0M$491.0M$326.0M$731.0M$1.3B
Other Assets$0$0$0$0$0$0$0$0
Total Liabilities$79.0M$191.0M$203.0M$146.0M$113.0M$181.0M$142.0M$163.0M
Current Liabilities$5.0M$35.0M$111.0M$93.0M$71.0M$86.0M$68.0M$83.0M
Borrowings$1.0M$21.0M$18.0M$18.0M$17.0M$85.0M$88.0M$82.0M
Other Liabilities$78.0M$170.0M$185.0M$128.0M$96.0M$96.0M$55.0M$81.0M
Equity$0$0$0$0$0$0$0$0
Reserves$-34.0M$-74.0M$284.0M$460.0M$490.0M$395.0M$836.0M$1.6B

For Kymera Therapeutics, Inc., operating cash flow was positive in 2 of 8 reported years; free cash flow in the latest year was negative at $234.0M; free cash flow was positive in 2 of 8 years.

Cash Flow Statement — 8 Years (USD millions)

Metric20182019202020212022202320242025
Operating Cash Flow$-18.0M$18.0M$88.0M$-129.0M$-153.0M$-103.0M$-195.0M$-233.0M
Investing Cash Flow$-3.0M$-17.0M$-432.0M$-101.0M$18.0M$105.0M$-417.0M$-523.0M
Financing Cash Flow$0$35.0M$0$8.0M$4.0M$4.0M$14.0M$0
Net Cash Flow$34.0M$36.0M$-45.0M$21.0M$20.0M$41.0M$10.0M$237.0M
Free Cash Flow$-19.0M$17.0M$79.0M$-131.0M$-156.0M$-137.0M$-207.0M$-234.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-6.12
EV / EBITDA-30.91
FCF Yield-2.62%
Quick Ratio9.91
Interest Coverage-1659.61
Return 1Y89.72%
Return 3Y638.24%
Return 5Y88.13%

Kymera Therapeutics, Inc. (KYMR) financials — frequently asked questions

What is Kymera Therapeutics, Inc.'s annual revenue?

Kymera Therapeutics, Inc. (KYMR) reported annual revenue of $39.0M in its most recent fiscal year.

What is Kymera Therapeutics, Inc.'s net profit?

Kymera Therapeutics, Inc. (KYMR) reported a net loss of $311.0M in its most recent fiscal year.

What is KYMR EV/EBITDA?

Kymera Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -30.91. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
KYMR Overview KYMR Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.